Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

METHODS: Three cancer cell lines derived from hematological malignancies (HH, DND-41, and MOLT-4 cells) were treated with Brentuximab vedotin (0.0068, 0.020, 0.068, 0.20, 0.68, 2.0, 6.8, 20, 68 nM, 72 hours) and cell viability was measured using the CellTiter-Glo luminescence assay.
RESULTS: Brentuximab vedotin reduced the viability of HH cells in a dose-dependent manner with an IC50 value of 0.058 nM, but did not reduce the viability of DND-41 and MOLT-4 cells. [3]

METHODS: Brentuximab vedotin (0.1 mg/kg, once a week, intravenously), chidamide (15 mg/kg, once a day, orally), or BV combined with chidamide were used to treat severe combined immunodeficient mice bearing tumor xenografts of HH cells mixed with BD Matrigel to study tumor growth in vivo.
RESULTS: The combination of brentuximab vedotin and chidamide effectively inhibited tumor growth. [3]

Human

Immobilized Human CD30 Protein (His) at 2 μg/mL (30 μL/well) can bind Brentuximab vedotin. The EC50 is 0.04460 μg/mL.

Monoclonal

MMAE